Abstract
A 69-year-old woman undergoing hemodialysis due to ANCA-associated nephritis and chronic renal failure developed lung adenocarcinoma and underwent radical surgery. Upon recurrence of her cancer, she received combination chemotherapy with carboplatin (CBDCA) 150 mg/m2 and docetaxel 35-70 mg/m2. Concentration of free CBDCA in serum was monitored for 6 days after drug administration. Hemodialysis was performed 1 hour after administration of CBDCA, and on day 4. Despite the lower maximum concentration, serum CBDCA levels 20-24 h after chemotherapy in this patient were 15 to 20 times higher than in subjects with normal renal function who received CBDCA at the area under the curve (AUC) of 5. She experienced moderate to severe nausea and vomiting which persisted for 12 days. During her second course of chemotherapy, hemodialysis was performed for 3 consecutive days after drug administration. The serum CBDCA levels on day 2 or later remained lower than in the first course, and the patient experienced fewer severe side effects. Based on the data from therapeutic drug monitoring of CBDCA, hemodialysis for 3 consecutive days after drug administration has been demonstrated to be useful for treatment of a patient with chronic renal failure receiving chemotherapy with CBDCA.
| Original language | English |
|---|---|
| Pages (from-to) | 1529-1532 |
| Number of pages | 4 |
| Journal | Japanese Journal of Cancer and Chemotherapy |
| Volume | 36 |
| Issue number | 9 |
| Publication status | Published - 2009 Sep |
Fingerprint
Keywords
- Area under the curve
- Carboplatin
- Chronic renal failure
- Hemodialysis
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Appropriate hemodialysis scheduling based on therapeutic drug monitoring of carboplatin in a patient with lung cancer and chronic renal failure. / Kamata, Hirofumi; Asano, Koichiro; Soejima, Kenzo; Shirahata, Toru; Nakatani, Michie; Inamoto, Hajime; Iketani, Osamu; Yamayoshi, Yasuko; Tanigawara, Yusuke; Ishizaka, Akitoshi.
In: Japanese Journal of Cancer and Chemotherapy, Vol. 36, No. 9, 09.2009, p. 1529-1532.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Appropriate hemodialysis scheduling based on therapeutic drug monitoring of carboplatin in a patient with lung cancer and chronic renal failure
AU - Kamata, Hirofumi
AU - Asano, Koichiro
AU - Soejima, Kenzo
AU - Shirahata, Toru
AU - Nakatani, Michie
AU - Inamoto, Hajime
AU - Iketani, Osamu
AU - Yamayoshi, Yasuko
AU - Tanigawara, Yusuke
AU - Ishizaka, Akitoshi
PY - 2009/9
Y1 - 2009/9
N2 - A 69-year-old woman undergoing hemodialysis due to ANCA-associated nephritis and chronic renal failure developed lung adenocarcinoma and underwent radical surgery. Upon recurrence of her cancer, she received combination chemotherapy with carboplatin (CBDCA) 150 mg/m2 and docetaxel 35-70 mg/m2. Concentration of free CBDCA in serum was monitored for 6 days after drug administration. Hemodialysis was performed 1 hour after administration of CBDCA, and on day 4. Despite the lower maximum concentration, serum CBDCA levels 20-24 h after chemotherapy in this patient were 15 to 20 times higher than in subjects with normal renal function who received CBDCA at the area under the curve (AUC) of 5. She experienced moderate to severe nausea and vomiting which persisted for 12 days. During her second course of chemotherapy, hemodialysis was performed for 3 consecutive days after drug administration. The serum CBDCA levels on day 2 or later remained lower than in the first course, and the patient experienced fewer severe side effects. Based on the data from therapeutic drug monitoring of CBDCA, hemodialysis for 3 consecutive days after drug administration has been demonstrated to be useful for treatment of a patient with chronic renal failure receiving chemotherapy with CBDCA.
AB - A 69-year-old woman undergoing hemodialysis due to ANCA-associated nephritis and chronic renal failure developed lung adenocarcinoma and underwent radical surgery. Upon recurrence of her cancer, she received combination chemotherapy with carboplatin (CBDCA) 150 mg/m2 and docetaxel 35-70 mg/m2. Concentration of free CBDCA in serum was monitored for 6 days after drug administration. Hemodialysis was performed 1 hour after administration of CBDCA, and on day 4. Despite the lower maximum concentration, serum CBDCA levels 20-24 h after chemotherapy in this patient were 15 to 20 times higher than in subjects with normal renal function who received CBDCA at the area under the curve (AUC) of 5. She experienced moderate to severe nausea and vomiting which persisted for 12 days. During her second course of chemotherapy, hemodialysis was performed for 3 consecutive days after drug administration. The serum CBDCA levels on day 2 or later remained lower than in the first course, and the patient experienced fewer severe side effects. Based on the data from therapeutic drug monitoring of CBDCA, hemodialysis for 3 consecutive days after drug administration has been demonstrated to be useful for treatment of a patient with chronic renal failure receiving chemotherapy with CBDCA.
KW - Area under the curve
KW - Carboplatin
KW - Chronic renal failure
KW - Hemodialysis
UR - http://www.scopus.com/inward/record.url?scp=79959847917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959847917&partnerID=8YFLogxK
M3 - Article
VL - 36
SP - 1529
EP - 1532
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
SN - 0385-0684
IS - 9
ER -